The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?
Gespeichert in:
| Veröffentlicht in: | American journal of kidney diseases 2012-05, Vol.59 (5), p.604-606 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 606 |
|---|---|
| container_issue | 5 |
| container_start_page | 604 |
| container_title | American journal of kidney diseases |
| container_volume | 59 |
| creator | Cohen, Robert A., MD, MSc Brown, Robert S., MD |
| description | |
| doi_str_mv | 10.1053/j.ajkd.2011.12.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1002504871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638611017793</els_id><sourcerecordid>1002504871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-78aaae46f6f468a09dbcd059c38eae32c8b7d5aca584165995f9be91727215473</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEokPhBVgg7yiLBP_EToIqUNVOYaSpqGbateWxbwZnkrjYSaV5Ex4XZ6awYMHKP_rOsXzOTZK3BGcEc_axyVSzMxnFhGSEZhiXz5IZ4ZSlomTl82SGaUFTwUpxkrwKocEYV0yIl8kJpUwQnNNZ8uvuB6D7Nbp2ziDVG3Tlxy26MJ3tbRi8Gqzr3we0smGH5o-qHQ83B_LGDnZ7PK4nErZ7dLaa36w_oFvvtl51yPZxq_RgNXxCVw4CWgxoBapt92jR18536DY6QD-Eg-XSdnY4PPbldfKiVm2AN0_raXJ_Pb-7_JYuv39dXF4sU51zPqRFqZSCXNSizkWpcGU22mBeaVaCAkZ1uSkMV1rxMieCVxWvqw1UpIjREJ4X7DQ5O_o-ePdzhDDIzgYNbat6cGOQBGPKcV4WJKL0iGrvQvBQywdvO-X3EZJTI7KRUyNyakQSKmMjUfTuyX_cdGD-Sv5UEIHzIwDxl48WvAw6JqLBWA96kMbZ__t__keu29idVu0O9hAaN_o-5ieJDFEg19NMTCNBCCZFUTH2GyZssQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1002504871</pqid></control><display><type>article</type><title>The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cohen, Robert A., MD, MSc ; Brown, Robert S., MD</creator><creatorcontrib>Cohen, Robert A., MD, MSc ; Brown, Robert S., MD</creatorcontrib><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2011.12.008</identifier><identifier>PMID: 22361042</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Chronic Disease ; Epoetin Alfa ; Erythropoietin - adverse effects ; Heart Failure - epidemiology ; Hematinics - adverse effects ; Humans ; Kidney Diseases - therapy ; Nephrology ; Patient Education as Topic - methods ; Physician-Patient Relations ; Recombinant Proteins - adverse effects ; Renal Dialysis ; Risk Assessment - methods ; Risk Factors ; Risk Management ; Stroke - epidemiology ; United States ; United States Food and Drug Administration</subject><ispartof>American journal of kidney diseases, 2012-05, Vol.59 (5), p.604-606</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2012 National Kidney Foundation, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-78aaae46f6f468a09dbcd059c38eae32c8b7d5aca584165995f9be91727215473</citedby><cites>FETCH-LOGICAL-c455t-78aaae46f6f468a09dbcd059c38eae32c8b7d5aca584165995f9be91727215473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0272638611017793$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22361042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Robert A., MD, MSc</creatorcontrib><creatorcontrib>Brown, Robert S., MD</creatorcontrib><title>The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><subject>Chronic Disease</subject><subject>Epoetin Alfa</subject><subject>Erythropoietin - adverse effects</subject><subject>Heart Failure - epidemiology</subject><subject>Hematinics - adverse effects</subject><subject>Humans</subject><subject>Kidney Diseases - therapy</subject><subject>Nephrology</subject><subject>Patient Education as Topic - methods</subject><subject>Physician-Patient Relations</subject><subject>Recombinant Proteins - adverse effects</subject><subject>Renal Dialysis</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Risk Management</subject><subject>Stroke - epidemiology</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1u1DAUhSMEokPhBVgg7yiLBP_EToIqUNVOYaSpqGbateWxbwZnkrjYSaV5Ex4XZ6awYMHKP_rOsXzOTZK3BGcEc_axyVSzMxnFhGSEZhiXz5IZ4ZSlomTl82SGaUFTwUpxkrwKocEYV0yIl8kJpUwQnNNZ8uvuB6D7Nbp2ziDVG3Tlxy26MJ3tbRi8Gqzr3we0smGH5o-qHQ83B_LGDnZ7PK4nErZ7dLaa36w_oFvvtl51yPZxq_RgNXxCVw4CWgxoBapt92jR18536DY6QD-Eg-XSdnY4PPbldfKiVm2AN0_raXJ_Pb-7_JYuv39dXF4sU51zPqRFqZSCXNSizkWpcGU22mBeaVaCAkZ1uSkMV1rxMieCVxWvqw1UpIjREJ4X7DQ5O_o-ePdzhDDIzgYNbat6cGOQBGPKcV4WJKL0iGrvQvBQywdvO-X3EZJTI7KRUyNyakQSKmMjUfTuyX_cdGD-Sv5UEIHzIwDxl48WvAw6JqLBWA96kMbZ__t__keu29idVu0O9hAaN_o-5ieJDFEg19NMTCNBCCZFUTH2GyZssQA</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Cohen, Robert A., MD, MSc</creator><creator>Brown, Robert S., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?</title><author>Cohen, Robert A., MD, MSc ; Brown, Robert S., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-78aaae46f6f468a09dbcd059c38eae32c8b7d5aca584165995f9be91727215473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Chronic Disease</topic><topic>Epoetin Alfa</topic><topic>Erythropoietin - adverse effects</topic><topic>Heart Failure - epidemiology</topic><topic>Hematinics - adverse effects</topic><topic>Humans</topic><topic>Kidney Diseases - therapy</topic><topic>Nephrology</topic><topic>Patient Education as Topic - methods</topic><topic>Physician-Patient Relations</topic><topic>Recombinant Proteins - adverse effects</topic><topic>Renal Dialysis</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Risk Management</topic><topic>Stroke - epidemiology</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Robert A., MD, MSc</creatorcontrib><creatorcontrib>Brown, Robert S., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Robert A., MD, MSc</au><au>Brown, Robert S., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>59</volume><issue>5</issue><spage>604</spage><epage>606</epage><pages>604-606</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22361042</pmid><doi>10.1053/j.ajkd.2011.12.008</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-6386 |
| ispartof | American journal of kidney diseases, 2012-05, Vol.59 (5), p.604-606 |
| issn | 0272-6386 1523-6838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1002504871 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Chronic Disease Epoetin Alfa Erythropoietin - adverse effects Heart Failure - epidemiology Hematinics - adverse effects Humans Kidney Diseases - therapy Nephrology Patient Education as Topic - methods Physician-Patient Relations Recombinant Proteins - adverse effects Renal Dialysis Risk Assessment - methods Risk Factors Risk Management Stroke - epidemiology United States United States Food and Drug Administration |
| title | The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T04%3A40%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20US%20Food%20and%20Drug%20Administration's%20Risk%20Evaluation%20and%20Mitigation%20Strategy%20(REMS)%20Program%20in%20Practice:%20Does%20It%20Really%20Inform%20Patients%20and%20Limit%20Risk?&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Cohen,%20Robert%20A.,%20MD,%20MSc&rft.date=2012-05-01&rft.volume=59&rft.issue=5&rft.spage=604&rft.epage=606&rft.pages=604-606&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2011.12.008&rft_dat=%3Cproquest_cross%3E1002504871%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1002504871&rft_id=info:pmid/22361042&rft_els_id=S0272638611017793&rfr_iscdi=true |